Silence Therapeutics (SLN)
(Delayed Data from NSDQ)
$21.61 USD
-0.02 (-0.07%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $21.57 -0.04 (-0.16%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
SLN 21.61 -0.02(-0.07%)
Will SLN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SLN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SLN
Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?
MediWound (MDWD) Moves 7.1% Higher: Will This Strength Last?
SLN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock?
Recursion Pharmaceuticals (RXRX) Surges 13.8%: Is This an Indication of Further Gains?
Strength Seen in Silence Therapeutics PLC Sponsored ADR (SLN): Can Its 15.4% Jump Turn into More Strength?
Other News for SLN
Beyond The Numbers: 7 Analysts Discuss Silence Therapeutics Stock
Silence Therapeutics Announces Upcoming AGM
3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)
Silence Therapeutics says additional results from APOLLO phase 1 study published